Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein

• Published in: BMJ evidence-based medicine Vol. 14; no. 2; p. 48
• Main Authors: Campbell-Scherer, Denise L, Montori, Victor M
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01.04.2009; BMJ Publishing Group LTD
• Subjects: Heart attacks; Proteins; Statins; Stroke; Women
• ISSN: 1356-5524; 2515-446X; 1473-6810; 2515-4478
• DOI: 10.1136/ebm.14.2.48

Patients: 17 802 men [= or >, slanted]50 years of age or women [= or >, slanted]60 years of age (mean age 66 y, 62% men) who had no history of cardiovascular (CV) disease, high-sensitivity C-reactive protein concentrations [= or >, slanted]2.0 mg/l, low-density lipoprotein cholesterol levels <3.4 mmol/l (130 mg/dl), and triglyceride concentrations <5.6 mmol/l (500 mg/dl). Outcomes Rates per 100 person-years At median 1.9 years Rosuvastatin Placebo RRR (95% CI) NNT (CI) Composite end point[dagger] 0.77 1.36 44% (31 to 54) 82 (67 to 116) Myocardial infarction 0.17 0.37 54% (30 to 70) 245 (189 to 440) Stroke 0.18 0.34 48% (21 to 66) 290 (211 to 664) Revascularisation 0.38 0.71 46% (28 to 59) 149 (116 to 245) Hospital admission for unstable angina 0.09 0.14 41% (-10 to 68) Not significant Confirmed cardiovascular death[double dagger] 0.19 0.23 18% (-27 to 48) Not significant All-cause death 1.00 1.25 20% (3 to 33) 183 (111 to 1220) *Abbreviations defined in glossary.